



FEB 28 2008

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet	1	of	2	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifeld
-------	---	----	---	----------------------	-----------------------------

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		6,399,630	B1	Macfarlane	06-04-2002
		6,653,292	B1	Krieg et al.	11-25-2003
		6,727,230	B1	Hutcherson et al.	04-27-2004
		6,821,957	B1	Krieg et al.	11-23-2004
		6,949,520	B1	Hartmann et al.	09-27-2005
		7,034,007	B1	Nyce et al.	04-25-2006
		2002-0091097	A1	Bratzler et al.	07-11-2002
		2002-0156033	A1	Bratzler et al.	10-24-2002
		2002-0164341	A1	Davis et al.	11-07-2002
		2002-0165178	A1	Schetter et al	11-07-2002
		2002-0198165	A1	Bratzler et al.	12-26-2002
		2003-0026801	A1	Weiner et al.	02-06-2003
		2003-0050263	A1	Krieg et al.	03-13-2003
		2003-0050268	A1	Krieg et al.	03-13-2003
		2003-0055014	A1	Bratzler	03-20-2003
		2003-0100527	A1	Krieg et al.	05-29-2003
		2003-0148316	A1	Lipford et al.	08-07-2003
		2003-0148976	A1	Krieg et al.	08-07-2003
		2003-0166001	A1	Lipford	09-04-2003
		2003-0181406	A1	Schetter et al.	09-25-2003
		2003-0191079	A1	Krieg et al.	10-09-2003
		2003-0232074	A1	Lipford et al.	12-18-2003
		2004-0030118	A1	Wagner et al.	02-12-2004
		2005-0277609	A1	Krieg et al.	12-15-2005
		2007-0065467	A1	Krieg et al.	03-22-2007
		2009-0017021	A1	Davis et al.	01-15-2009

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
		WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
		WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
				FILING DATE: February 2, 2002	CONFIRMATION NO.: 7139
				APPLICANT: Robert L. Bratzler et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifeld
Sheet	2	of	3		

		WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
		WO	00/67023	A1 P	CPG Immunopharmaceuticals GMBH	11-09-2000	
		WO	03/043572	A2	3M Innovative Properties Company	05-30-2003	
		WO	2008/139262	A2	Coley Pharmaceutical GMBH	11-20-2008	

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		ARORA et al., Immunomodulation by liposome entrapped allergen. Mol Cell Biochem. 1990 Sep 21;97(2):173-9. Abstract Only.	
		CHO et al., Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion. J Allergy Clin Immunol. 2001 Nov;108(5):697-702.	
		DOERSCHUG et al., Asthma guidelines: an assessment of physician understanding and practice. Am J Respir Crit Care Med. 1999 Jun;159(6):1735-41.	
		FONSECA et al., Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev. 2009 Jan 9. [Epub ahead of print]. 7 pages.	
		GAVETT et al., Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med. 1995 Nov 1;182(5):1527-36.	
		KLINE, Effects of CpG DNA on Th1/Th2 balance in asthma. In Immunobiology of Bacterial CpG-DNA, Ed. H. Wagner. Springer. 2000;247:211-25..	
		KLINE et al., Ch. 26: DNA Immunomodulation of asthma. In Inflammatory Mechanisms in Allergic Diseases. Ed., Zeiman et al. Marcel Dekker, Inc. 2002;551-64.	
		KLINE, Immunotherapy of asthma using CpG oligodeoxynucleotides. Immunol Res. 2007;39(1-3):279-86. Review.	
		KLINE et al., Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008 Oct;21(8):434-9.	
		KOU et al., [Analysis and regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma] Arerugi. 1994 Mar;43(3):482-91. Japanese. Abstract Only.	Y- Abstract
		KRIEG et al., CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-60.	
		KRIEG et al., P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides. 2003;13(6):491-9.	
		KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
		KRIEG, Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007 Jul;4(3):289-94.	
		KRIEG, Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007 May;117(5):1184-94.	
		KRIEG, Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb;1(1):56-63.	
		KRIEG, How to exclude immunostimulatory and other nonantisense effects of antisense	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: February 2, 2002	CONFIRMATION NO.: 7139
				APPLICANT: Robert L. Bratzler et al.	
Sheet	3	of	3	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifeld

	oligonucleotides. Manual of Antisense. 1999:79-89.	
	KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2001 Nov 8;19(6):618-22.	
	KRIEG, Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52.	
	KRIEG, Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.	
	KRIEG, Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008 Jan 7;27(2):161-7. Review.	
	MILGROM et al., Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999 Dec 23;341(26):1966-73. Abstract only.	
	SJÖLANDER et al., Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol. 1997 Apr 10;177(1):69-76.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.